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In normal somatic cells telomere shortening occurs with each cell
division whereas immortalized, permanently growing cell lines
demonstrate maintenance of telomeric sequences with stabiliza-
tion of their telomeric lengths at highly variable levels ranging
from a few to >20 kbp in individual cell lines. In order to compen-
sate for the telomere shortening that occurs upon cell division due
to the ‘end replication problem’ a specific activity with the ability
to add new telomeric T2AG3 sequences to the ends of the chromo-
somes is needed (Levy et al, 1992). In most cases this function is
executed by telomerase, a ribonucleoprotein complex with reverse
transcriptase activity (Morin, 1989). Telomerase expression is a
characteristic feature of permanent cell lines and a vast majority
human malignant tumours whereas most normal somatic tissues
have been found negative (Kim et al, 1994). Specific somatic cells
like activated B and T lymphocytes and certain stem cells also
exhibit telomerase activity (Hiyama et al, 1995b; Härle-Bachor
and Boukamp, 1996; Norrback and Roos, 1997). However, despite
the expression of telomerase these cell types have been shown to
undergo telomere attrition both in vivo and in vitro although
possibly at a decreased rate (Vaziri et al, 1994; Weng et al, 1995;
Norrback and Roos, 1997). The only exception appears to be
germinal centre B-cells which have been reported to exhibit
telomere elongation (Weng et al, 1997). A fraction of in vitro
immortalized human cells have been reported to exhibit alternative
telomere length maintenance mechanisms independent of telo-
merase (ALT), but in vivo such a phenotype, characterized by
extremely long and heterogenous telomeres, seems to be rare
(Mehle et al, 1996; Bryan and Reddel, 1997; Bryan et al, 1997).
In order for normal cells, lacking telomerase activity, to become
immortal it has been proposed, based on in vitro studies, that two
proliferative lifespan barriers, mortality stage M1 and M2, have 
to be overcome. After a certain number of cell divisions the
telomeres would have shortened to a minimum length and this
shortening will signal to the cells to enter M1, i.e. senescence. The
senescent cell is characterized by cell cycle arrest, resistance to
undergo apoptosis and can remain viable for a long period of time.
Depending on the specific cell-type, functional p53 and/or Rb
proteins are essential for entry into senescence and inactivation of
these tumour suppressors will allow the cells to escape the M1-
barrier and undergo further rounds of cell division (Wynford-
Thomas, 1997). These cells will acquire critically shortened
telomeres resulting in a proliferative crisis with massive cell death.
Rare cells which have reactivated telomerase will escape the M2-
barrier and become immortal.
The expression level of hTERT, the catalytic subunit of the
telomerase complex, seems to be present in limiting amounts and
is strongly correlated to the level of telomerase activity (Meyerson
et al, 1997). Introduction of hTERT into normal cells lacking
telomerase has been found to give a prolonged lifespan, far beyond
that of normal cells, proving the linkage between telomere length
and replicative lifespan (Bodnar at al, 1998; Morales et al, 1999).
In these cells the senescence barrier is circumvented but is still
intact and the cells can be induced to senesce if the telomerase
expression is turned off with subsequent telomere shortening.
Since telomerase is strongly associated with malignancy it has
been identified as a potential target for anti-tumour therapy. A
number of anti-telomerase treatment approaches, such as anti-
sense oligonucleotides and reverse transcriptase inhibitors have
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different permanent cell lines (Feng et al, 1995; Strahl and
Blackburn, 1996). Also, other ways of inhibiting the action of
telomerase are emerging like DNA tetraplex interacting agents
(Jean-Louis and Claude, 1998). A scenario is thereby envisioned
where the tumour mass is reduced in size by surgery or
chemotherapy whereafter inhibition of telomerase is expected to
result in progressive telomere shortening and induction of senes-
cence or cell death in the remaining tumour cells before a potential
relapse would appear. Whether the effect of the anti-telomerase
drugs will be induction of senescence or crisis and cell death
depends on whether the tumour cells possess an intact senescence
programme.
For two reasons fairly short telomeres in the tumour cells to be
treated is a prerequisite for a successful clinical outcome using
anti-telomerase treatment strategies. Firstly, only tumour cells
with short telomeres could be induced to senesce or undergo cell
death after a limited number of cell divisions. Secondly, anti-
telomerase drugs will lead to telomere shortening of the telom-
erase-positive stem cells as well and the drugs must be effective
before severely damaging normal stem cells. Comparisons of
normal and tumour tissues have generally demonstrated shorter
telomeres in the tumour samples, but some tumours have demon-
strated similar or extended telomere lengths (Hiyama et al, 1995a;
Mehle et al, 1996; Norrback and Roos, 1997; Bryan et al, 1997).
Thus, telomere length estimations should be performed on the
tumour tissue before anti-telomerase treatment is instituted in
order to select cases suitable for this type of therapy.
So far no studies have been performed to assess the role and
suitability of anti-telomerase drugs in the clinical setting of tumour
therapy. By analysing the telomere length status of lymphomas at
diagnosis and at subsequent relapses, predictions can be made
concerning the suitability of anti-telomerase therapy. A simple
interpretation would be that for patients with short telomeres in the
relapse tumour material anti-telomerase treatment could have been
beneficial, whereas this is less likely for cases with intermediate or
long telomeres. We decided to analyse this in a series of diagnostic
malignant lymphomas, including 16 relapse cases, which were
analysed with respect to telomere length. Considerable individual
differences concerning telomere peak lengths of the lymphomas
were observed whereas the mean telomere length values showed
less variation. At relapse constant, shortened or lengthened
telomeres were found. These data implicate that anti-telomerase
therapy will be effective in only a fraction of malignant
lymphomas.
MATERIALS AND METHODS
Samples
Tumour DNA was isolated at diagnosis from 47 malignant
lymphomas, nine samples from benign lymphoid tissues and from
two to five samples from 16 patients with relapsing B- or T-cell
lymphomas. From 14 out of the 16 relapsing lymphomas diag-
nostic samples were available and were thus included in the group
with diagnostic lymphomas. The samples were mainly from
lymph nodes but also material from bone marrow, peripheral blood
and pleural effusions were obtained. All cases were characterized
by immunophenotyping using flow cytometry and a panel of
monoclonal antibodies directed against various surface antigens.
Based on the immunophenotype the fraction of malignant cells
could be estimated in each sample. The lymphomas were classi-
fied according to the REAL classification (Harris et al, 1994). At
diagnosis, 22 cases were small cell lymphomas (12 follicular
follicle centre cell lymphomas, five chronic lymphocytic
leukaemias, four lymphoplasmacytoid lymphomas and one mantle
cell lymphoma) and 19 were large cell lymphomas. Six cases had
Hodgkin’s disease. Morphologic diagnoses for the 16 relapsing
lymphomas are given in Table 2.
Telomere length measurements
Southern blotting, hybridization using a telomeric probe and
calculations of mean telomere length and peak telomere length
were performed as described (Mehle et al, 1996). Briefly, 10 mg of
restriction enzyme-digested genomic DNA of a sample were
loaded onto 0.7% agarose gels. After Southern transfer the telo-
meric fragments were detected through hybridization with the
telomeric probe (TTAGGG)4. The autoradiographs were scanned
(Personal Densitometer, Molecular Dynamics, USA) and the mean
telomere length of a sample was calculated over the range of 2–
23 kbp. Telomere peak lengths were measured by estimating the
band size corresponding to the point with the highest optical
density within the peak. In order to check for adequate DNA frag-
mentation by the restriction enzymes and to normalize for differ-
ences in DNA loading filters were hybridized with a microsatellite
probe, (CAC)5 as described (Mehle et al, 1996).
Telomerase activity measurements
Protein measurements and preparation of extracts were performed
as described (Norrback et al, 1996). All extracts were diluted to
0.14 mg protein ml–1 and were analysed at 0.28 mg assay–1, which is
within the linear range of the assay, as described (Wright et al,
1995; Holt et al, 1996; Norrback et al, 1998). The polymerase
chain reaction (PCR)-based Telomeric Repeat Amplification
Protocol (TRAP) was made semi-quantitative with inclusion of the
Internal Telomerase Assay Standard (ITAS) used at 15 attograms
assay–1 as described (Wright et al, 1995; Norrback et al, 1998). The
telomerase activity value is the ratio between the amplified telo-
merase products and the amplified ITAS product. The telomerase
activity value of a sample is the mean of two or more analyses.
Telomerase positive cell lines and RNAse incubation of selected
samples to prove the RNA-template dependency of telomerase in
the formation of telomeric products were controls used in the
study in addition to the internal standard.
RESULTS
The 47 diagnostic lymphoma samples demonstrated similar mean
telomere lengths in the different diagnostic subgroups with mean
lengths varying from 5.1 to 5.4 kbp (Table 1). For the benign
lymphoid tissues this figure was 7.9 kbp. All the separate lymphoma
subgroups exhibited significantly shortened telomeres compared to
the benign samples (P < 0.01 using Mann–Whitney). All the benign
samples exhibited one peak and the length of the peaks ranged from
6.9 to 12.6 kbp. A more heterogenous picture emerged concerning
peak lengths of the lymphomas which exhibited one or multiple
peaks that ranged in length from 2.4 to >23 kbp and considerable
individual differences were observed (Tables 1 and 2). Also within
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were seen. Thus, no obvious differences were seen regarding
telomere profile patterns in the lymphoma subgroups at diagnosis.
Concerning samples obtained from the 16 relapsing cases a
summary of data regarding the source of tumour material, time
from diagnosis, morphologic grading and percentage of tumour
cells based on immunophenotyping is given in Table 2. In the
relapse group the first sample exhibited peak lengths that ranged
from 2.4 to >23 kbp whereas the mean telomere length values
showed less variation, from 3.8 to 6.7 kbp, indicating that the cell
populations in general harboured chromosomes with a large varia-
tion in the length of their telomeres.
In the relapsing lymphomas we decided to determine peak
length changes in order to be able to study different populations 
of cells with unique telomere profiles within a sample, since
lymphomas consist of a tumour component as well as normal cells.
Studying the peak length changes in the relapsing lymphomas
most cases could be divided into samples which exhibited peaks
that were stable, decreased or increased in length, even though half
of the relapse lymphomas exhibited two peaks while the other half
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Table 1 Telomere lengths in diagnostic subgroups of malignant lymphomas and in samples
from benign lymphoid tissues
Telomere length (kbp)
Diagnosis Number Mean length Peak length
Mean Range Rangea
Small cell lymphoma 22 5.1 4.0–6.3 2.4–>23.0
Large cell lymphoma 19 5.4 3.8–6.5 2.4–>23.0
Hodgkin’s disease 6 5.4 4.8–6.0 6.2–15.3
Benign lymphoid tissue 9 7.9 6.1–9.0 6.9–12.6
a The lymphomas exhibited one or multiple peaks and the peak range values given are the
shortest and the longest peaks observed within the subclassified samples. All the benign cases
exhibited one broad telomere peak. Due to the presence of lymphoma samples with multiple
peaks, mean peak values for the different groups were not calculated. The differences in mean
telomere lengths between the lymphoma subgroups and the benign lymphoid tissues were all
significant at the 0.01 level.
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Figure 1 Patient no. 1 demonstrating remarkably stable telomeres upon relapse and ongoing telomerase activity. (A) Patient no. 1 demonstrating unchanged
telomere profiles during a period of 57 months in five different samples. Lane 1, diagnostic lymph node sample. Lane 2, lymph node sample 40 months after
diagnosis. Lane 3, bone marrow sample 57 months after diagnosis. Lane 4, peripheral blood sample 57 months after diagnosis. Lane 5, pleura effusion sample
57 months after diagnosis. Southern blotting using (TTAGGG)4 probe. Telomere length profiles were obtained by densitometry and were compensated for DNA
loading in each individual lane. OD = optical density. (B) Patient no. 1 demonstrating telomerase activity at diagnosis and at relapse 40 months later. Lane 1,
diagnostic lymph node sample. Lane 2, lymph node sample 40 months after diagnosis. Lane C, negative control (lysis buffer). The level of telomerase activity
was analysed at 0.28 mg protein assay–1 using the TRAP-assay and the internal standard, ITAS at 15 attograms assay–1only exhibited one peak. Deviations of <1 kbp in telomere peak
values between different samples were observed in five cases (nos
1, 3, 5, 9, 10; Figure 1A) indicating fairly stable telomere lengths
during the course of the disease and six relapsing tumours (nos 6,
7, 12, 14, 15, 16; Figure 2A) demonstrated decreasing peak
lengths. Case No. 13 exhibited one stable and very short peak
while the longer peak was lost at relapse. Case no. 2 showed
increasing telomere peak length while three cases (nos 4, 8, 11;
Figure 2B) showed two populations, one with increasing and one
with decreasing peak lengths when compared with the respective
diagnostic sample. A summary of peak and mean telomere lengths
for the relapsing lymphomas are presented in Table 2.
All relapsing lymphomas studied except one demonstrated
significant telomerase activity (Table 2). The relative telomerase
activity in 0.28 mg protein extract per reaction varied from 0 to
4.88. When the fraction of malignant cells was taken into account
the activity was estimated to be from 0 to 12.19, assuming that the
normal cells were telomerase negative or had negligible activity.
The relapse data are difficult to describe for the whole group
due to the individual character of each case why selected patients
are shortly commented below.
Patient 1 was followed for a total time of 57 months and in five
samples taken during this time period a remarkable stability in
peak lengths were demonstrated in lymph node, bone marrow,
peripheral blood and pleural exudate samples (Table 2 and Figure
1A). Telomerase activity was detected at diagnosis and at relapse
after 40 months (Figure 1B).
Patient 13 showed at both diagnosis and relapse a population of
cells with very short and stable telomeres. In the diagnostic sample
a second cell population with very long telomeres was present
which was lost at relapse. Only in the relapse sample could telom-
erase activity be detected (Table 2).
Patient 12 had a lymphoblastic lymphoma showing an obvious
reduction in peak lengths in relapse samples from testis and bone
marrow (Table 2). The peak length reduction was similar in both
compartments.
Patient 4 was diagnosed with a lymphoma showing two peaks
at 10.8 and 4.3 kbp. At relapse the telomere profile was broader
with a peak at about 8 kbp (Table 2 and Figure 2B). The fraction of
monoclonal B-cells was 40% at relapse compared with 80% at
diagnosis, but no peak between 3 and 5 kbp could be revealed
indicating a telomere length increase in the population of cells
which exhibited the shorter telomere profile.
DISCUSSION
In the present study the telomere lengths of diagnostic lymphoma
samples and benign lymphoid tissue samples were assessed and
when comparing the mean telomere lengths of the lymphomas
with the benign tissues a significant telomere shortening was
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Figure 2 Compared to the diagnostic samples both decreased and increased telomere lengths were observed in the relapsing tumours. (A) Patient no. 14
demonstrating a decrease in telomere length at relapse. Lane 1, diagnostic lymph node sample. Lane 2, lymph node sample 43 months after diagnosis. 
(B) Patient no. 4 showing an increased telomere length at relapse. Lane 1, diagnostic lymph node sample. Lane 2, lymph node sample 47 months after
diagnosis. Southern blotting using (TTAGGG)4 probe. Telomere length profiles were obtained by densitometry and were compensated for DNA loading in each
individual lane. OD = optical density
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2observed in all of the lymphoma subgroups. In addition peak
lengths and mean telomere lengths as well as telomerase activity
were measured in two to five samples from relapsing non-
Hodgkin’s lymphomas. The mean telomere length calculation
gives a mean value for all telomere ends of all cells in a sample but
since lymphoma samples are an admixture between malignant and
normal cells the measure is not very informative concerning the
telomere lengths of the specific cell populations. Also, since the
telomere lengths in the lymphomas were spread over a large kbp
range rather large peak value changes gives a small impact on the
mean telomere length value. When describing the telomere
dynamics of specific cell populations in tissue samples consisting
of different cell populations the peak telomere value is the measure
of choice. Thus the telomere dynamics of specific cell populations
in the 16 relapsing lymphomas were studied concerning the peak
lengths. The relapsing lymphomas which all exhibited one or two
telomere peaks could be divided into tumours showing stable,
decreasing or increasing telomere peak lengths. It was found that
all the benign lymphoid tissues exhibited only one broad peak. For
the malignant lymphomas the immunophenotyping data were
informative because the number of neoplastic cells compared to
the number of normal cells corresponded in many cases to the size
of the telomere peaks observed. A telomere peak length below 
5.0 kbp can be considered to be derived from malignant cells since
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Table 2 A summary of relevant data concerning 16 cases with relapsing non-Hodgkin’s lymphomas
Patient Sample Sourcea Time Diagnosisc Tumour Telomere length (kbp) Telomerase Adjusted
(m)b cells Peak Mean activitye telomerase
(%)d activityf
1 1 LN 0 LCBL 40 4.4 4.6 4.88 12.2
2 LN 40 LPL 52 4.1 4.2 0.94 1.8
3 BM 57 LPL 64 4 4.3 ND ND
4 PB 57 LPL 72 4.1 4.1 ND ND
5 PL 57 LPL 71 4.2 4.3 ND ND
2 1 LN 0 LCBL 40 4.3 4.4 ND ND
2 PB 11 MBC 36 6.8 5.1 ND ND
3 1 LN 36 LCBL >50 5.8 5.3 ND ND
2 LN 85 LCBL ND 5.8 4.9 1.73 ND
4 1 LN 0 FCL >80 10.8 + 4.3 4.7 ND ND
2 LN 47 FCL 40 8 5.6 ND ND
5 1 PL 0 LCTL 70 13.8 + 7.8 5.7 ND ND
2 PL 7 LCTL 70 14.7 + 7.5 6.1 ND ND
6 1 LN 0 LCTL 65 11.1 5.9 0.14 0.21
2 PL 0 LCTL 51 10.4 6.3 ND ND
3 PL 8 LCTL 78 9 5.8 ND ND
4 PL 11 LCTL 57 8.5 5 ND ND
7 1 Tonsil 0 FCL 40 >23 + 8 5.9 ND ND
2 LN 67 FCL 60 7.5 + 3.3 4.5 0.32 0.53
8 1 LN 10 FCL 30 12.2 6.7 ND ND
2 LN 68 FCL ND ND ND 2.20 ND
3 PL 89 FCL 20 15.8 + 9.6 5.5 ND ND
4 LN 89 FCL 80 17.3 + 8.4 6.2 1.61 2.01
5 LN 102 FCL 30 8.2 5.3 1.04 3.45
9 1 LN 0 LCBL 60 2.4 3.8 ND ND
2 PB 26 MBC >80 2.8 3.5 ND ND
10 1 LN 0 MCL 50 6.3 5.3 0.42 0.85
2 Skin 24 MCL 47 6.9 5.3 0.96 2.05
11 1 LN 0 LCBL 50 8.2 4.8 0.93 1.85
2 LN 14 LCBL 75 8.2 + 2.2 4.2 ND ND
3 LN 32 LCBL 47 8.5 + 2.9 4 0.31 0.66
4 LN 35 LCBL 85 9.8 + 3 4 1.91 2.25
12 1 LN 0 LCTL 50 11.8 6.4 ND ND
2 Testis 22 LCTL 65 7.1 5.4 ND ND
3 BM 22 LCTL 60 6.8 5.9 0.24 1.02
13 1 LN 0 FCL 65 >23 + 2.4 5 0 0
2 LN 26 FCL 90 2.4 3.7 0.70 0.78
14 1 LN 0 LCBL ND 10.3 5.8 ND ND
2 LN 43 FCL 40 10.8 + 4.9 4.7 0.64 1.60
15 1 LN 0 FCL 80 8.2 + 5 5 ND ND
2 PL 25 LCBL 70 6.2 + 2.6 4 ND ND
3 LN 25 FCL 35 ND ND 0.17 0.49
16 1 LN 0 FCL 45 14.6 6.3 0.52 1.15
2 LN 48 LCBL 30 6.8 4.6 0.11 0.38
3 LN 73 FCL 30 ND ND 0.74 2.45
aIN, lymph node; BM, bone marrow; PB, peripheral blood; PL, pleura fluid. bTime in months from diagnosis. cLBCL, large B-cell lymphoma; LPL,
lymphoplasmacytoid lymphoma; FCL, follicle cell lymphoma; LTCL, large T-cell lymphoma; MCL, mantle cell lymphoma; MBC, monoclonal B-cells detected by
flow cytometry. dJudged by immunophenotyping and flow cytometry. eRelative activity. fTelomerase activity value divided by the percentage of tumour cells. ND =
not done or inconclusive.not even normal cells from centenarians exhibit such short telo-
meres (Vaziri et al, 1993; Slagboom et al, 1994). Populations with
increasing peak values can also be concluded to be derived from
tumour cells since telomere elongation in tumour cells can occur
while normal haematopoietic cells exhibit telomere shortening
except for normal germinal centre B-cells which are rare in the
lymphoma samples (Vaziri et al, 1993; Slagboom et al, 1994;
Allsopp et al, 1995; Hiyama et al, 1995a; Bryan et al, 1997; Weng
et al, 1997). Based on these assumptions it was possible to deter-
mine which peaks belonged to normal versus malignant cells in
most of the relapsing lymphomas. In the remaining cases we
assume that the telomere profiles of the tumour cells resembled
those of the normal cells since all these lymphomas except one had
a tumour cell fraction of 40% or more and if the tumour cells
exhibited a differing telomere profile compared with the normal
cells two peaks should have been observed.
Considerable individual differences with respect to the number
of peaks as well as peak lengths were found within the diagnostic
lymphoma samples, unrelated to morphologic subclassification
(peak length, range = 2.4 to > 23 kbp; Table 1). The benign cases
by comparison all demonstrated one peak which ranged in length
from 6.9 to 12.6 kbp. The difference in age of the patients (12–83
years) from which the benign samples were obtained explains
most of the variation in peak length since the telomere length
decreases in lymphocytes with age (Vaziri et al, 1993; Slagboom 
et al, 1994; Allsopp et al, 1995). The large variability seen at diag-
nosis could be due to malignant transformation in cells with either
overall short or long telomeres, which might be a consequence of
the number of cell divisions undergone before the transformation
event occurred. Thus, one lymphoma might develop from a cell
recently recruited from the bone marrow giving a tumour with
longer telomeres, whereas another lymphoma evolves from a
lymphocyte with a history of many previous cell generations
leading to a lymphoma with shorter telomeres.
The telomere dynamics of cells are believed to be influenced by
the expression level of telomerase and differing levels of telo-
merase activity in the diagnostic lymphomas could also explain
the telomere length variability seen. We have previously shown
that non-Hodgkin’s lymphomas exhibit increased levels of telom-
erase activity compared to benign lymph nodes (Norrback et al,
1996), a finding further verified in the present study (not shown in
figures). The major source of telomerase activity in non-malignant
lymphoid tissues is normal germinal centre B-cells which should
be low in numbers in the lymphoma samples and thus the activity
measured can for the most part be denoted to the tumour compo-
nent (Norrback et al, 1996). In in vitro manipulation experiments it
has been shown that in addition to telomerase activity telomere
binding proteins can affect the telomere length of cells but it is not
known to what extent tumours exhibit abberant functioning of
such proteins (van Steensel and de Lange, 1997; Gravel et al,
1998; LaBranche et al, 1998).
The impact of telomerase activity on the telomere length in our
relapsing lymphomas is not obvious from the data presented here,
since there are cases with strong telomerase activity which still
exhibit significant reduction of the telomere length by time.
However, for cases with unchanged or increased telomere lengths
ongoing telomerase activity in the tumour cells is one explanation
(Figure 1 A,B). Due to the high sensitivity of the TRAP assay
(Kim et al, 1994), the activity found is present in a cell fraction of
unknown size and there is a theoretical possibility that as little as
0.1–1% telomerase-positive cells can be detected. A strict compar-
ison between telomere length values, which are based on DNA
extracted from the whole cell population, and telomerase activity
must for this reason be made with caution. However, in the
relapsing lymphomas the telomerase activity was of such a magni-
tude that it is reasonable to believe that a significant fraction of the
lymphoma cells de facto had telomerase activity.
One alternative explanation for the telomere length alterations
demonstrated in the relapsing lymphomas is that there is a selec-
tive loss of cells due to cytostatic therapy or radiation treatment
and that the surviving subclones have a certain telomere length
constitution which later is manifested in the relapse tumour cell
population. This selection of therapy-resistant cells is probably
random at the telomere length level. In most of our relapse cases
we have performed immunoglobulin gene rearrangement studies
and DNA fingerprinting analysis, showing that the original clone
is preserved but that clonal changes not seldom occur by time
which can support the idea of selective loss and repopulation
(Rosenquist, 1998). The diagnostic samples from patients 7 and 13
both contained a potential ALT population which exhibited a peak
length beyond 23 kbp and cells with shorter telomeres (Table 2). It
is interesting to note that upon relapse the potential ALT cells were
lost while the cells with the shorter telomere profiles prevailed.
In the future we can foresee the development of telomerase
inhibitors for use in the treatment of malignant diseases. Anti-
telomerase drugs are expected to be the most effective if they are
used to treat tumours with short telomeres and are administered
after the tumour burden has been reduced using conventional
therapy. Theoretically tumours can be divided into two main groups
according to their expected suitability as targets for anti-telomerase
treatment. The first group represents tumours which have been
derived from a telomerase-negative cell and would be expected to
frequently reactivate telomerase late in tumorigenesis after the
senescence barrier has been inactivated. Inhibition of telomerase in
these tumours would have a cytotoxic effect on the tumour cells.
The other group of tumours are either derived from stem cells or
other telomerase competent cells and would be expected to retain
telomerase expression throughout tumorigenesis. These tumours
would be expected to much more frequently possess an intact
senescence programme and exhibit longer telomeres compared to
the tumours in the first group. Telomerase inhibition in these
tumours would have a delayed cytostatic effect.
Lymphomas belong to the second group of tumours since
normal lymphocytes express telomerase upon cell cycle progres-
sion whereas it is possible that many solid tumours belong to the
first group described and thus would be more suitable targets for
anti-telomerase therapy. In the present study however, six out of
16 malignant lymphomas exhibited decreased telomere peak
lengths upon relapse and only four of the relapsed tumours showed
peak lengths below 6.0 kbp. This indicates that only a fraction of
these tumours would have been suitable targets for telomerase
inhibition treatment. It should be noted that we cannot exclude the
possibility that a few of the relapsing lymphomas significantly
elongated their telomeres through the action of telomerase and that
the use of telomerase inhibitors could have prevented the relapse.
Due to these findings however, the telomere length of relapsing
tumours after conventional therapy is an important field of 
investigation. Such studies will ultimately determine the extent at
which anti-telomerase drugs will become successful therapeutic
regimens in the clinical setting.
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